TARS3 Human Pre-designed siRNA Set A contains three designed siRNAs for TARS3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TAS1R1 Human Pre-designed siRNA Set A contains three designed siRNAs for TAS1R1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TAS1R2 Human Pre-designed siRNA Set A contains three designed siRNAs for TAS1R2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TAS1R3 Human Pre-designed siRNA Set A contains three designed siRNAs for TAS1R3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TAS2R1 Human Pre-designed siRNA Set A contains three designed siRNAs for TAS2R1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TAS2R10 Human Pre-designed siRNA Set A contains three designed siRNAs for TAS2R10 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TAS2R14 Human Pre-designed siRNA Set A contains three designed siRNAs for TAS2R14 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TAS2R38 Human Pre-designed siRNA Set A contains three designed siRNAs for TAS2R38 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TAS2R5 Human Pre-designed siRNA Set A contains three designed siRNAs for TAS2R5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TAS2R7 Human Pre-designed siRNA Set A contains three designed siRNAs for TAS2R7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TASL Human Pre-designed siRNA Set A contains three designed siRNAs for TASL gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TASOR Human Pre-designed siRNA Set A contains three designed siRNAs for TASOR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TASOR2 Human Pre-designed siRNA Set A contains three designed siRNAs for TASOR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TASP1 Human Pre-designed siRNA Set A contains three designed siRNAs for TASP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tasquinimod-d3 (ABR-215050-d3) is the deuterium labeled Tasquinimod (HY-10528). Tasquinimod is an oral antiangiogenic agent, which plays an important role in castration-resistant prostate cancer. Tasquinimod binds to the regulatory Zn2+ binding domain of HDAC4 with Kd of 10-30 nM. Tasquinimod also is a S100A9 inhibitor[1][2][3].

Tasquinimod-d3 (ABR-215050-d3) is the deuterium labeled Tasquinimod (HY-10528). Tasquinimod is an oral antiangiogenic agent, which plays an important role in castration-resistant prostate cancer. Tasquinimod binds to the regulatory Zn2+ binding domain of HDAC4 with Kd of 10-30 nM. Tasquinimod also is a S100A9 inhibitor[1][2][3].

TAT Human Pre-designed siRNA Set A contains three designed siRNAs for TAT gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tat-NTS peptide is a cell-penetrating peptide with neuroprotective effects. Tat-NTS peptide can specifically inhibit the nuclear translocation of ANXA1 and reduce neuronal apoptosis in ischemic areas. Moreover, Tat-NTS peptide can reduce the volume of cerebral ischemic infarction and can be used in the research of ischemic stroke[1].

TAT-P110, a peptide inhibitor of Drp1-Fis1 interaction, reduces pathology in numerous models of neurodegeneration, ischemia, and sepsis without blocking the physiological functions of Drp1[1].

TAT-p16 (p16INK4a peptide) is a peptide mimic of p16INK4a that can induce an early G[1] phase cell cycle arrest in the absence of active cyclin E:Cdk2 complex[1].

TATDN1 Human Pre-designed siRNA Set A contains three designed siRNAs for TATDN1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TAX1BP1 Human Pre-designed siRNA Set A contains three designed siRNAs for TAX1BP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TAX1BP3 Human Pre-designed siRNA Set A contains three designed siRNAs for TAX1BP3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tazemetostat (EPZ-6438) is a potent, selective and orally available EZH2 inhibitor. Tazemetostat inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a Ki value of 2.5 nM. Tazemetostat inhibits EZH2 with IC50s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat inhibits rat EZH2 with an IC50 […]

Tazemetostat (EPZ-6438) is a potent, selective and orally available EZH2 inhibitor. Tazemetostat inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a Ki value of 2.5 nM. Tazemetostat inhibits EZH2 with IC50s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat inhibits rat EZH2 with an IC50 […]

Tazemetostat (EPZ-6438) is a potent, selective and orally available EZH2 inhibitor. Tazemetostat inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a Ki value of 2.5 nM. Tazemetostat inhibits EZH2 with IC50s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat inhibits rat EZH2 with an IC50 […]

Tazemetostat (EPZ-6438) is a potent, selective and orally available EZH2 inhibitor. Tazemetostat inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a Ki value of 2.5 nM. Tazemetostat inhibits EZH2 with IC50s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat inhibits rat EZH2 with an IC50 […]

Tazemetostat (EPZ-6438) is a potent, selective and orally available EZH2 inhibitor. Tazemetostat inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a Ki value of 2.5 nM. Tazemetostat inhibits EZH2 with IC50s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat inhibits rat EZH2 with an IC50 […]

Tazemetostat (EPZ-6438) is a potent, selective and orally available EZH2 inhibitor. Tazemetostat inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a Ki value of 2.5 nM. Tazemetostat inhibits EZH2 with IC50s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat inhibits rat EZH2 with an IC50 […]

TBATA Human Pre-designed siRNA Set A contains three designed siRNAs for TBATA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TBC1D1 Human Pre-designed siRNA Set A contains three designed siRNAs for TBC1D1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TBC1D10B Human Pre-designed siRNA Set A contains three designed siRNAs for TBC1D10B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TBC1D15 Human Pre-designed siRNA Set A contains three designed siRNAs for TBC1D15 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TBC1D16 Human Pre-designed siRNA Set A contains three designed siRNAs for TBC1D16 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TBC1D2 Human Pre-designed siRNA Set A contains three designed siRNAs for TBC1D2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TBC1D20 Human Pre-designed siRNA Set A contains three designed siRNAs for TBC1D20 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TBC1D22A Human Pre-designed siRNA Set A contains three designed siRNAs for TBC1D22A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TBC1D23 Human Pre-designed siRNA Set A contains three designed siRNAs for TBC1D23 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TBC1D24 Human Pre-designed siRNA Set A contains three designed siRNAs for TBC1D24 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TBC1D25 Human Pre-designed siRNA Set A contains three designed siRNAs for TBC1D25 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TBC1D2B Human Pre-designed siRNA Set A contains three designed siRNAs for TBC1D2B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TBC1D3 Human Pre-designed siRNA Set A contains three designed siRNAs for TBC1D3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TBC1D31 Human Pre-designed siRNA Set A contains three designed siRNAs for TBC1D31 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TBC1D3B Human Pre-designed siRNA Set A contains three designed siRNAs for TBC1D3B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TBC1D4 Human Pre-designed siRNA Set A contains three designed siRNAs for TBC1D4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TBC1D5 Human Pre-designed siRNA Set A contains three designed siRNAs for TBC1D5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.